APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Anti-Neoplastic Pharmaceutical Agent

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Anti-Neoplastic Pharmaceutical Agent Industry Growth and Trends Forecast to 2032

Report ID 173965220123 December 2025124 pages

Choose your research edition.

Industry ResearchAnti-Neoplastic Pharmaceutical Agent Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Neoplastic Pharmaceutical Agent Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Anti-Neoplastic Pharmaceutical Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Neoplastic Pharmaceutical Agent Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Neoplastic Pharmaceutical Agent Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

According to APO Research, the global Anti-Neoplastic Pharmaceutical Agent market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Anti-Neoplastic Pharmaceutical Agent is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Anti-Neoplastic Pharmaceutical Agent is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Neoplastic Pharmaceutical Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Anti-Neoplastic Pharmaceutical Agent market include Innovent, Takeda, Johnson & Johnson, Novartis, Merck KGaA, Roche, Eli Lilly, Pfizer and Hengrui Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Anti-Neoplastic Pharmaceutical Agent market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Anti-Neoplastic Pharmaceutical Agent market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Anti-Neoplastic Pharmaceutical Agent market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Anti-Neoplastic Pharmaceutical Agent.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Anti-Neoplastic Pharmaceutical Agent market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Anti-Neoplastic Pharmaceutical Agent Market by Company

Innovent

Takeda

Johnson & Johnson

Novartis

Merck KGaA

Roche

Eli Lilly

Pfizer

Hengrui Medicine

GSK

Bristol-Myers Squibb

Amgen

AbbVie

AstraZeneca

Seagen

Regeneron

Ono Pharmaceutical

Merck & Co

Gilead Sciences

Exelixis

Anti-Neoplastic Pharmaceutical Agent Segment by Type

Cancer Immunotherapy

Chemotherapy

Targeted Therapy

Other

Anti-Neoplastic Pharmaceutical Agent Segment by Application

Blood-related Cancer

Breast Cancer

Prostate Cancer

Lung Cancer

Other

Anti-Neoplastic Pharmaceutical Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Neoplastic Pharmaceutical Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Neoplastic Pharmaceutical Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Neoplastic Pharmaceutical Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Anti-Neoplastic Pharmaceutical Agent companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Anti-Neoplastic Pharmaceutical Agent Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Anti-Neoplastic Pharmaceutical Agent Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Anti-Neoplastic Pharmaceutical Agent Market Share by Region (2021-2026) Table 4. Global Anti-Neoplastic Pharmaceutical Agent Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Anti-Neoplastic Pharmaceutical Agent Market Share by Region (2027-2032) Table 6. Global Anti-Neoplastic Pharmaceutical Agent Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Anti-Neoplastic Pharmaceutical Agent Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Anti-Neoplastic Pharmaceutical Agent Market Size Share by Type (2021-2026) Table 9. Global Anti-Neoplastic Pharmaceutical Agent Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Anti-Neoplastic Pharmaceutical Agent Market Size Share Forecasted by Type (2027-2032) Table 11. North America Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Anti-Neoplastic Pharmaceutical Agent Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Anti-Neoplastic Pharmaceutical Agent Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Anti-Neoplastic Pharmaceutical Agent Market Size Share by Application (2021-2026) Table 24. Global Anti-Neoplastic Pharmaceutical Agent Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Anti-Neoplastic Pharmaceutical Agent Market Size Share Forecasted by Application (2027-2032) Table 26. North America Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Anti-Neoplastic Pharmaceutical Agent Industry Trends Table 37. Anti-Neoplastic Pharmaceutical Agent Industry Drivers Table 38. Anti-Neoplastic Pharmaceutical Agent Industry Opportunities and Challenges Table 39. Anti-Neoplastic Pharmaceutical Agent Industry Restraints Table 40. Global Anti-Neoplastic Pharmaceutical Agent Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Anti-Neoplastic Pharmaceutical Agent Revenue Market Share by Company (2021-2026) Table 42. Global Anti-Neoplastic Pharmaceutical Agent Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Anti-Neoplastic Pharmaceutical Agent Key Company Headquarters & Area Served Table 44. Global Anti-Neoplastic Pharmaceutical Agent Company, Product Type & Application Table 45. Global Anti-Neoplastic Pharmaceutical Agent Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Anti-Neoplastic Pharmaceutical Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Innovent Company Information Table 49. Innovent Business Overview Table 50. Innovent Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Innovent Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 52. Innovent Recent Development Table 53. Takeda Company Information Table 54. Takeda Business Overview Table 55. Takeda Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Takeda Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 57. Takeda Recent Development Table 58. Johnson & Johnson Company Information Table 59. Johnson & Johnson Business Overview Table 60. Johnson & Johnson Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Johnson & Johnson Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 62. Johnson & Johnson Recent Development Table 63. Novartis Company Information Table 64. Novartis Business Overview Table 65. Novartis Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Novartis Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 67. Novartis Recent Development Table 68. Merck KGaA Company Information Table 69. Merck KGaA Business Overview Table 70. Merck KGaA Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Merck KGaA Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 72. Merck KGaA Recent Development Table 73. Roche Company Information Table 74. Roche Business Overview Table 75. Roche Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Roche Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 77. Roche Recent Development Table 78. Eli Lilly Company Information Table 79. Eli Lilly Business Overview Table 80. Eli Lilly Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Eli Lilly Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 82. Eli Lilly Recent Development Table 83. Pfizer Company Information Table 84. Pfizer Business Overview Table 85. Pfizer Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Pfizer Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 87. Pfizer Recent Development Table 88. Hengrui Medicine Company Information Table 89. Hengrui Medicine Business Overview Table 90. Hengrui Medicine Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Hengrui Medicine Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 92. Hengrui Medicine Recent Development Table 93. GSK Company Information Table 94. GSK Business Overview Table 95. GSK Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. GSK Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 97. GSK Recent Development Table 98. Bristol-Myers Squibb Company Information Table 99. Bristol-Myers Squibb Business Overview Table 100. Bristol-Myers Squibb Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Bristol-Myers Squibb Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 102. Bristol-Myers Squibb Recent Development Table 103. Amgen Company Information Table 104. Amgen Business Overview Table 105. Amgen Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Amgen Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 107. Amgen Recent Development Table 108. AbbVie Company Information Table 109. AbbVie Business Overview Table 110. AbbVie Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. AbbVie Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 112. AbbVie Recent Development Table 113. AstraZeneca Company Information Table 114. AstraZeneca Business Overview Table 115. AstraZeneca Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. AstraZeneca Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 117. AstraZeneca Recent Development Table 118. Seagen Company Information Table 119. Seagen Business Overview Table 120. Seagen Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Seagen Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 122. Seagen Recent Development Table 123. Regeneron Company Information Table 124. Regeneron Business Overview Table 125. Regeneron Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Regeneron Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 127. Regeneron Recent Development Table 128. Ono Pharmaceutical Company Information Table 129. Ono Pharmaceutical Business Overview Table 130. Ono Pharmaceutical Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Ono Pharmaceutical Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 132. Ono Pharmaceutical Recent Development Table 133. Merck & Co Company Information Table 134. Merck & Co Business Overview Table 135. Merck & Co Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Merck & Co Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 137. Merck & Co Recent Development Table 138. Gilead Sciences Company Information Table 139. Gilead Sciences Business Overview Table 140. Gilead Sciences Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Gilead Sciences Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 142. Gilead Sciences Recent Development Table 143. Exelixis Company Information Table 144. Exelixis Business Overview Table 145. Exelixis Anti-Neoplastic Pharmaceutical Agent Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Exelixis Anti-Neoplastic Pharmaceutical Agent Product Portfolio Table 147. Exelixis Recent Development Table 148. North America Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. North America Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2021-2026) & (US$ Million) Table 150. North America Anti-Neoplastic Pharmaceutical Agent Market Share by Country (2021-2026) Table 151. North America Anti-Neoplastic Pharmaceutical Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. North America Anti-Neoplastic Pharmaceutical Agent Market Share Forecast by Country (2027-2032) Table 153. Europe Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Europe Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2021-2026) & (US$ Million) Table 155. Europe Anti-Neoplastic Pharmaceutical Agent Market Share by Country (2021-2026) Table 156. Europe Anti-Neoplastic Pharmaceutical Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Europe Anti-Neoplastic Pharmaceutical Agent Market Share Forecast by Country (2027-2032) Table 158. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2021-2026) & (US$ Million) Table 160. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Share by Country (2021-2026) Table 161. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Share Forecast by Country (2027-2032) Table 163. Latin America Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Latin America Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2021-2026) & (US$ Million) Table 165. Latin America Anti-Neoplastic Pharmaceutical Agent Market Share by Country (2021-2026) Table 166. Latin America Anti-Neoplastic Pharmaceutical Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Latin America Anti-Neoplastic Pharmaceutical Agent Market Share Forecast by Country (2027-2032) Table 168. Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2021-2026) & (US$ Million) Table 170. Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Share by Country (2021-2026) Table 171. Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Share Forecast by Country (2027-2032) Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Anti-Neoplastic Pharmaceutical Agent Product Image Figure 3. Global Anti-Neoplastic Pharmaceutical Agent Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Anti-Neoplastic Pharmaceutical Agent Market Size (2021-2032) & (US$ Million) Figure 5. Global Anti-Neoplastic Pharmaceutical Agent Market Share by Region: 2025 VS 2032 Figure 6. Global Anti-Neoplastic Pharmaceutical Agent Market Share by Region (2021-2032) Figure 7. North America Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Cancer Immunotherapy Image Figure 13. Global Cancer Immunotherapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Chemotherapy Image Figure 15. Global Chemotherapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Targeted Therapy Image Figure 17. Global Targeted Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Other Image Figure 19. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Global Anti-Neoplastic Pharmaceutical Agent Market Size Overview by Type (2021-2032) & (US$ Million) Figure 21. Global Anti-Neoplastic Pharmaceutical Agent Market Share by Type 2025 VS 2032 Figure 22. North America Anti-Neoplastic Pharmaceutical Agent Market Size Share by Type (2021-2032) Figure 23. Europe Anti-Neoplastic Pharmaceutical Agent Market Size Share by Type (2021-2032) Figure 24. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size Share by Type (2021-2032) Figure 25. Latin America Anti-Neoplastic Pharmaceutical Agent Market Size Share by Type (2021-2032) Figure 26. Middle East and Africa Anti-Neoplastic Pharmaceutical Agent Market Size Share by Type (2021-2032) Figure 27. Blood-related Cancer Image Figure 28. Global Blood-related Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Breast Cancer Image Figure 30. Global Breast Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Prostate Cancer Image Figure 32. Global Prostate Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Lung Cancer Image Figure 34. Global Lung Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Other Image Figure 36. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Global Anti-Neoplastic Pharmaceutical Agent Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Anti-Neoplastic Pharmaceutical Agent Market Share by Application 2025 VS 2032 Figure 39. North America Anti-Neoplastic Pharmaceutical Agent Market Size Share by Application (2021-2032) Figure 40. Europe Anti-Neoplastic Pharmaceutical Agent Market Size Share by Application (2021-2032) Figure 41. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size Share by Application (2021-2032) Figure 42. Latin America Anti-Neoplastic Pharmaceutical Agent Market Size Share by Application (2021-2032) Figure 43. Middle East and Africa Anti-Neoplastic Pharmaceutical Agent Market Size Share by Application (2021-2032) Figure 44. Global Top 5 and 10 Anti-Neoplastic Pharmaceutical Agent Players Market Share by Revenue in 2025 Figure 45. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 46. North America Anti-Neoplastic Pharmaceutical Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. North America Anti-Neoplastic Pharmaceutical Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. North America Anti-Neoplastic Pharmaceutical Agent Market Share by Country (2021-2032) Figure 49. Europe Anti-Neoplastic Pharmaceutical Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Anti-Neoplastic Pharmaceutical Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Anti-Neoplastic Pharmaceutical Agent Market Share by Country (2021-2032) Figure 52. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Share by Country (2021-2032) Figure 55. Latin America Anti-Neoplastic Pharmaceutical Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Anti-Neoplastic Pharmaceutical Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Anti-Neoplastic Pharmaceutical Agent Market Share by Country (2021-2032) Figure 58. Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 60. Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Share by Country (2021-2032) Figure 61. Years Considered Figure 62. Research Process Figure 63. Key Executives Interviewed

Scope & coverage.

Types
  • Cancer Immunotherapy
  • Chemotherapy
  • Targeted Therapy
  • Other
Applications
  • Blood-related Cancer
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Other
Companies covered
  • Innovent
  • Takeda
  • Johnson & Johnson
  • Novartis
  • Merck KGaA
  • Roche
  • Eli Lilly
  • Pfizer
  • Hengrui Medicine
  • GSK
  • Bristol-Myers Squibb
  • Amgen
  • AbbVie
  • AstraZeneca
  • Seagen
  • Regeneron
  • Ono Pharmaceutical
  • Merck & Co
  • Gilead Sciences
  • Exelixis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Anti-Neoplastic Pharmaceutical Agent Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Anti-Neoplastic Pharmaceutical Agent Market Size by Region (2021-2032)
  5. 1.4.1 Global Anti-Neoplastic Pharmaceutical Agent Market Size by Region (2021-2026)
  6. 1.4.2 Global Anti-Neoplastic Pharmaceutical Agent Market Size by Region (2027-2032)
  7. 1.5 Key Regions Anti-Neoplastic Pharmaceutical Agent Market Size (2021-2032)
  8. 1.5.1 North America Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (2021-2032)
2 Anti-Neoplastic Pharmaceutical Agent Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Cancer Immunotherapy
  3. 2.1.2 Chemotherapy
  4. 2.1.3 Targeted Therapy
  5. 2.1.4 Other
  6. 2.2 Global Anti-Neoplastic Pharmaceutical Agent Market Size by Type
  7. 2.2.1 Global Anti-Neoplastic Pharmaceutical Agent Market Size Overview by Type (2021-2032)
  8. 2.2.2 Global Anti-Neoplastic Pharmaceutical Agent Historic Market Size Review by Type (2021-2026)
  9. 2.2.3 Global Anti-Neoplastic Pharmaceutical Agent Market Size Forecasted by Type (2027-2032)
  10. 2.3 Global Anti-Neoplastic Pharmaceutical Agent Market Size by Regions
  11. 2.3.1 North America Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Type (2021-2026)
  12. 2.3.2 Europe Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Type (2021-2026)
  13. 2.3.3 Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Type (2021-2026)
  14. 2.3.4 South America Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Type (2021-2026)
  15. 2.3.5 Middle East and Africa Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Type (2021-2026)
3 Anti-Neoplastic Pharmaceutical Agent Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Blood-related Cancer
  3. 3.1.2 Breast Cancer
  4. 3.1.3 Prostate Cancer
  5. 3.1.4 Lung Cancer
  6. 3.1.5 Other
  7. 3.2 Global Anti-Neoplastic Pharmaceutical Agent Market Size by Application
  8. 3.2.1 Global Anti-Neoplastic Pharmaceutical Agent Market Size Overview by Application (2021-2032)
  9. 3.2.2 Global Anti-Neoplastic Pharmaceutical Agent Historic Market Size Review by Application (2021-2026)
  10. 3.2.3 Global Anti-Neoplastic Pharmaceutical Agent Market Size Forecasted by Application (2027-2032)
  11. 3.3 Global Anti-Neoplastic Pharmaceutical Agent Market Size by Regions
  12. 3.3.1 North America Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Application (2021-2026)
  13. 3.3.2 Europe Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Application (2021-2026)
  14. 3.3.3 Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Application (2021-2026)
  15. 3.3.4 South America Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Application (2021-2026)
  16. 3.3.5 Middle East and Africa Anti-Neoplastic Pharmaceutical Agent Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Anti-Neoplastic Pharmaceutical Agent Industry Trends
  2. 4.2 Anti-Neoplastic Pharmaceutical Agent Industry Drivers
  3. 4.3 Anti-Neoplastic Pharmaceutical Agent Industry Opportunities and Challenges
  4. 4.4 Anti-Neoplastic Pharmaceutical Agent Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Anti-Neoplastic Pharmaceutical Agent Revenue (2021-2026)
  2. 5.2 Global Anti-Neoplastic Pharmaceutical Agent Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Anti-Neoplastic Pharmaceutical Agent Key Company Headquarters & Area Served
  4. 5.4 Global Anti-Neoplastic Pharmaceutical Agent Company, Product Type & Application
  5. 5.5 Global Anti-Neoplastic Pharmaceutical Agent Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Anti-Neoplastic Pharmaceutical Agent Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Anti-Neoplastic Pharmaceutical Agent Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Anti-Neoplastic Pharmaceutical Agent Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Innovent
  2. 6.1.1 Innovent Company Information
  3. 6.1.2 Innovent Business Overview
  4. 6.1.3 Innovent Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Innovent Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  6. 6.1.5 Innovent Recent Developments
  7. 6.2 Takeda
  8. 6.2.1 Takeda Company Information
  9. 6.2.2 Takeda Business Overview
  10. 6.2.3 Takeda Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Takeda Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  12. 6.2.5 Takeda Recent Developments
  13. 6.3 Johnson & Johnson
  14. 6.3.1 Johnson & Johnson Company Information
  15. 6.3.2 Johnson & Johnson Business Overview
  16. 6.3.3 Johnson & Johnson Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Johnson & Johnson Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  18. 6.3.5 Johnson & Johnson Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Novartis Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Merck KGaA
  26. 6.5.1 Merck KGaA Company Information
  27. 6.5.2 Merck KGaA Business Overview
  28. 6.5.3 Merck KGaA Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Merck KGaA Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  30. 6.5.5 Merck KGaA Recent Developments
  31. 6.6 Roche
  32. 6.6.1 Roche Company Information
  33. 6.6.2 Roche Business Overview
  34. 6.6.3 Roche Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Roche Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  36. 6.6.5 Roche Recent Developments
  37. 6.7 Eli Lilly
  38. 6.7.1 Eli Lilly Company Information
  39. 6.7.2 Eli Lilly Business Overview
  40. 6.7.3 Eli Lilly Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Eli Lilly Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  42. 6.7.5 Eli Lilly Recent Developments
  43. 6.8 Pfizer
  44. 6.8.1 Pfizer Company Information
  45. 6.8.2 Pfizer Business Overview
  46. 6.8.3 Pfizer Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Pfizer Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  48. 6.8.5 Pfizer Recent Developments
  49. 6.9 Hengrui Medicine
  50. 6.9.1 Hengrui Medicine Company Information
  51. 6.9.2 Hengrui Medicine Business Overview
  52. 6.9.3 Hengrui Medicine Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Hengrui Medicine Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  54. 6.9.5 Hengrui Medicine Recent Developments
  55. 6.10 GSK
  56. 6.10.1 GSK Company Information
  57. 6.10.2 GSK Business Overview
  58. 6.10.3 GSK Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 GSK Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  60. 6.10.5 GSK Recent Developments
  61. 6.11 Bristol-Myers Squibb
  62. 6.11.1 Bristol-Myers Squibb Company Information
  63. 6.11.2 Bristol-Myers Squibb Business Overview
  64. 6.11.3 Bristol-Myers Squibb Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Bristol-Myers Squibb Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  66. 6.11.5 Bristol-Myers Squibb Recent Developments
  67. 6.12 Amgen
  68. 6.12.1 Amgen Company Information
  69. 6.12.2 Amgen Business Overview
  70. 6.12.3 Amgen Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Amgen Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  72. 6.12.5 Amgen Recent Developments
  73. 6.13 AbbVie
  74. 6.13.1 AbbVie Company Information
  75. 6.13.2 AbbVie Business Overview
  76. 6.13.3 AbbVie Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 AbbVie Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  78. 6.13.5 AbbVie Recent Developments
  79. 6.14 AstraZeneca
  80. 6.14.1 AstraZeneca Company Information
  81. 6.14.2 AstraZeneca Business Overview
  82. 6.14.3 AstraZeneca Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 AstraZeneca Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  84. 6.14.5 AstraZeneca Recent Developments
  85. 6.15 Seagen
  86. 6.15.1 Seagen Company Information
  87. 6.15.2 Seagen Business Overview
  88. 6.15.3 Seagen Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Seagen Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  90. 6.15.5 Seagen Recent Developments
  91. 6.16 Regeneron
  92. 6.16.1 Regeneron Company Information
  93. 6.16.2 Regeneron Business Overview
  94. 6.16.3 Regeneron Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Regeneron Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  96. 6.16.5 Regeneron Recent Developments
  97. 6.17 Ono Pharmaceutical
  98. 6.17.1 Ono Pharmaceutical Company Information
  99. 6.17.2 Ono Pharmaceutical Business Overview
  100. 6.17.3 Ono Pharmaceutical Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Ono Pharmaceutical Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  102. 6.17.5 Ono Pharmaceutical Recent Developments
  103. 6.18 Merck & Co
  104. 6.18.1 Merck & Co Company Information
  105. 6.18.2 Merck & Co Business Overview
  106. 6.18.3 Merck & Co Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Merck & Co Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  108. 6.18.5 Merck & Co Recent Developments
  109. 6.19 Gilead Sciences
  110. 6.19.1 Gilead Sciences Company Information
  111. 6.19.2 Gilead Sciences Business Overview
  112. 6.19.3 Gilead Sciences Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Gilead Sciences Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  114. 6.19.5 Gilead Sciences Recent Developments
  115. 6.20 Exelixis
  116. 6.20.1 Exelixis Company Information
  117. 6.20.2 Exelixis Business Overview
  118. 6.20.3 Exelixis Anti-Neoplastic Pharmaceutical Agent Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Exelixis Anti-Neoplastic Pharmaceutical Agent Product Portfolio
  120. 6.20.5 Exelixis Recent Developments
7 North America
  1. 7.1 North America Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2021-2026)
  3. 7.3 North America Anti-Neoplastic Pharmaceutical Agent Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2021-2026)
  3. 8.3 Europe Anti-Neoplastic Pharmaceutical Agent Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2021-2026)
  3. 10.3 South America Anti-Neoplastic Pharmaceutical Agent Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst